3.52% volatility in Trevi Therapeutics Inc (TRVI) last month: This is a red flag warning

On Friday, Trevi Therapeutics Inc (NASDAQ: TRVI) opened higher 4.31% from the last session, before settling in for the closing price of $6.03. Price fluctuations for TRVI have ranged from $2.30 to $7.39 over the past 52 weeks.

Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.

Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!

Get the FREE Report with all the details here.


Sponsored

Company’s average yearly earnings per share was noted 8.09% at the time writing. With a float of $59.67 million, this company’s outstanding shares have now reached $99.89 million.

Let’s look at the performance matrix of the company that is accounted for 26 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.

Trevi Therapeutics Inc (TRVI) Insider Updates

A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Trevi Therapeutics Inc is 41.36%, while institutional ownership is 51.48%. The most recent insider transaction that took place on Mar 25 ’25, was worth 17,365. In this transaction Chief Scientific Officer of this company sold 2,631 shares at a rate of $6.60, taking the stock ownership to the 221,373 shares. Before that another transaction happened on Mar 21 ’25, when Company’s President & CEO sold 5,263 for $6.58, making the entire transaction worth $34,625. This insider now owns 213,313 shares in total.

Trevi Therapeutics Inc (TRVI) Performance Highlights and Predictions

Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.11 per share during the current fiscal year.

According to the Wall Street analysts, stocks earnings will be around 8.09% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will plunge by -12.18% during the next five years compared to 27.09% growth over the previous five years of trading.

Trevi Therapeutics Inc (NASDAQ: TRVI) Trading Performance Indicators

Check out the current performance indicators for Trevi Therapeutics Inc (TRVI). In the past quarter, the stock posted a quick ratio of 15.38.

For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -0.45, a number that is poised to hit -0.10 in the next quarter and is forecasted to reach -0.56 in one year’s time.

Technical Analysis of Trevi Therapeutics Inc (TRVI)

Trevi Therapeutics Inc (NASDAQ: TRVI) saw its 5-day average volume 0.93 million, a negative change from its year-to-date volume of 1.73 million. As of the previous 9 days, the stock’s Stochastic %D was 18.80%. Additionally, its Average True Range was 0.39.

During the past 100 days, Trevi Therapeutics Inc’s (TRVI) raw stochastic average was set at 71.93%, which indicates a significant increase from 32.86% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 46.54% in the past 14 days, which was lower than the 78.85% volatility it showed in the past 100 days.

At the time of writing, stock’s 50-day Moving Average is $6.33, while its 200-day Moving Average is $4.22. Nevertheless, the first resistance level for the watch stands at $6.45 in the near term. At $6.60, the stock is likely to face the second major resistance level. The third major resistance level sits at $6.90. If the price goes on to break the first support level at $6.00, it is likely to go to the next support level at $5.70. Assuming the price breaks the second support level, the third support level stands at $5.55.

Trevi Therapeutics Inc (NASDAQ: TRVI) Key Stats

There are currently 99,893K shares outstanding in the company with a market cap of 639.97 million. Presently, the company’s annual sales total 0 K according to its annual income of -47,910 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -10,340 K.

News Daemon
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.